HealthFinders Collaborative and Free Clinic of Steele County Pursue Merger.
Boards approve a merger between two local community health organizations to improve access and services.
(FARIBAULT, Minn.) May 11, 2021 – The boards of directors of both the Free Clinic of Steele County, based in Owatonna and HealthFinders Collaborative, based in Faribault have agreed to pursue a merger. The merger is expected to formally close by the end of June 2021. It will result in a stronger combined entity able to serve more communities and patients. The combined organization will be led by the current HealthFinders Collaborative Executive Director, Charlie Mandile, and his leadership team. It will use the HealthFinders Collaborative brand.
“I am very excited by this opportunity,” said Mandile. “Both the Free Clinic of Steele County and HealthFinders Collaborative are committed to providing high-quality care to families who are often on the margins of our health care system. Together, we will be able to increase access and expand services to more people who need them. The Free Clinic and HealthFinders Collaborative share very similar missions and values. The opportunity to expand access to medical care to our neighbors who need it is the driving force behind this merger.”
Both HealthFinders Collaborative and the Free Clinic of Steele County leverage volunteer providers such as nurse practitioners, dentists and physicians to offer services to patients who otherwise would not have access. Regardless of insurance coverage or spoken language, the community-based clinics provide essential education, advocacy and access to high-quality care.
“Bringing these two entities together is a huge step forward for our communities,” said Dr. Brian Bunkers, President and CEO of Mayo Clinic Health Systems in Faribault and Owatonna. “They have similar objectives and values and merging will give them the synergy needed to take each organization to an even higher level of service.”
HealthFinders Collaborative services in Faribault and Northfield will experience no changes in services or operations as a result of the merger. All existing appointments and services will continue without interruption. The Free Clinic will launch more consistent and coordinated scheduling and accelerate needed process improvements such as electronic medical records and phone and volunteer scheduling infrastructure as part of the merger process.
“Our model is based on local community engagement,” said Mandile, “and as we expand to Owatonna, this will continue to be central to our work. We are committed to hiring local staff and engaging the local community.”
About HealthFinders Collaborative
HealthFinders Collaborative (HFC), is a community health center that provides a comprehensive primary access point to health services for the marginalized families of Rice County. Through primary care, medication assistance, patient education and advocacy, and community-based wellness programming, HFC works across the continuum of wellness to collaborate and engage communities in their own health. In 2018, HealthFinders provided medical and dental care valued at over $575,000. While patients and insurance were able to cover a portion of that care, donors supported over $400,000 in discounts, so no patient was turned away. Learn more at https://healthfindersmn.org/.
About Free Clinic of Steele County
The Free Clinic of Steele County serves primarily adult uninsured residents of Steele County and provides chronic disease management (high blood pressure, diabetes, high cholesterol, mild depression) and other non-life-threatening medical conditions. The clinical care team includes health care professionals from different backgrounds, including registered nurses, health promoters, social workers, dental hygienists, medical lab technologists and physicians. The volunteer organization has offices in Owatonna and is generously supported by the United Way of Steele County and the May Clinic Health System.
Khiron Comments on the Results of Project Twenty21 – UK´s Largest Observational Study into Medical Cannabis Products
Khiron is a founding member of Project Twenty 21 and was the first supplier of EU-GMP high-THC dried cannabis flower to the study
The findings show that medical Cannabis dramatically improves quality of life for people with life-limiting conditions, including Chronic Pain, Multiple Sclerosis, Tourette's Syndrome and PTSD
Legal prescriptions allow patients to access medical cannabis without engaging in criminality and to avoid dependency associated with other medicines commonly prescribed for these debilitating conditions
TORONTO, May 11, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, applauds the publication today in the accredited scientific journal "Psychopharmacology" of the first findings arising from Project Twenty 21, UK's first and largest national medical cannabis registry that was launched on November 7, 2019 at the Royal College of Psychiatrists in London.
Khiron Comments on the Results of Project Twenty21 – UK´s Largest Observational Study into Medical Cannabis Products
Through Project Twenty21, eligible patients can access affordable medical cannabis treatment, monitored by Drug Science, UK's leading independent scientific body. The project aims to create the UK's largest body of evidence for the effectiveness and tolerability of medical cannabis to warrant NHS funding where the benefits of treatment with medical cannabis are proven to outweigh the potential risks.
The Project Twenty 21 study has now licensed prescriptions of medical cannabis to over 900 patients who are in substantially poorer health than the general population, and who have been unable to manage their diagnosed conditions with commonly prescribed medicines. The findings show that legally prescribed cannabis provides clinically significant improvements in the quality of life of patients living with conditions such as Chronic Pain, Multiple Sclerosis, Tourette's Syndrome, Epilepsy and Post Traumatic Stress Disorder (PTSD). Based on the early positive momentum of the Project Twety21, Khiron will be launching other commercial initiatives to reach as many people as possible in the country.
The patient data collected show that medical cannabis improves the quality of life more than classical treatments do, for example for neuropathic pain. According to the National Institute for Clinical Excellence (NICE), there is little or no evidence that commonly prescribed drugs, such as benzodiazepines or opioids, make any difference to people's quality of life, pain or psychological distress, but they can cause harm, including possible addiction. In contrast, the results of Project Twenty21 clearly show a fifty percent increase in patients' self-reported health and ability to lead a more normal life as well as significant improvements in patients' ability to manage debilitating secondary conditions such as anxiety, insomnia and depression. Also, patients are now able to avoid criminality with legal prescriptions, as many have felt compelled to turn to illegal use to manage their conditions.
Project leader of Twenty21 Professor David Nutt from Drug Science, comments: "A lack of clinical evidence has made it difficult for doctors to confidently prescribe legal medical cannabis in the UK. These new findings provide a major step forward and help to clarify the benefit these medicines can have for thousands of seriously ill patients."
Tejinder Virk, President of Khiron Europe, says: "We are glad to see our strong commitment with medical research bear its fruits with this publication. Khiron is a true pioneer in the medical cannabis landscape in the UK, and not just because of its products. Our biggest contribution to improve access to medical cannabis in the UK is our education programs for prescribing clinicians and the dissemination of our expertise with cannabis-based therapeutics. We plan to continue our data-driven approach with the deployment of EU-GMP cannabinoid-based medicines based on our Colombian extracts, whose efficacy and safety are backed by clinical data collected in our wholly-owned clinics with over 17,000 prescriptions."
With this prescriber-oriented and patient-centered approach, Khiron has made a reputation in the UK as a leader in medical cannabis training thanks to its educational platform, Khiron Academy, providing CPD-certified education to collaborative partners such as the Medical Cannabis Clinicians Society (MCCS) and Cellen. For further details on the results and methodology of Project Twenty21, please see: https://www.drugscience.org.uk/wp-content/uploads/2021/05/213_2021_5855_OnlinePDF-2.pdf
About Khiron Life Sciences Corp. Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Colombia, Peru, Germany and the United Kingdom, and is positioned to commence sales in Mexico and Brazil in 2021.
Leveraging wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with KuidaTMnow marketed in multiple jurisdictions in Latin America, the US and United Kingdom. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Khiron Europe: Tejinder Virk Europe President E: tvirk@khiron.ca
SOURCE Khiron Life Sciences Corp.
MindBeacon launches new Digital Alcohol Use Management Therapy Program in consultation with experts from the Centre for Addiction and Mental health
Toronto, May 11, 2021 (GLOBE NEWSWIRE) -- MindBeacon Holdings Inc. (TSX: MBCN), leading provider of digital mental and behavioural health therapy, today announced the launch of a new digital therapy targeting alcohol use. Developed in consultation with experts at The Centre for Addiction and Mental Health (CAMH), the new program uses the principles of cognitive behavioural therapy (CBT) and a harm reduction approach to manage alcohol consumption and develop strategies to cope with cravings.
New research on substance use during the pandemic suggests alcohol consumption among Canadians has increased since the onset of the pandemic with nearly a quarter (24 per cent) of Canadians reporting increased alcohol consumption (Statistics Canada). Crafted by a team of psychologists and social workers at MindBeacon in consultation with addiction experts at CAMH, the “Managing Alcohol Use” program is designed to help Canadians build healthy relationships with alcohol. The eight to twelve-week Therapist Guided Program combines leading cognitive behavioural principles to equip Canadians with mild to moderate alcohol usage habits with the skills to manage thoughts, behaviours and physical symptoms associated with drinking by creating strategies to monitor daily intake, identify triggers and set goals.
"The Managing Alcohol Use program is an innovative digitally-delivered therapy to focus on alcohol use and provide evidence-based solutions for Canadians looking to change their relationship with alcohol and lead a healthier life,” says Dr Peter Farvolden PhD, CPsych, Chief Science Officer of MindBeacon. “Canadians are turning to alcohol to manage stress, ease boredom and contend with irregular schedules. Social isolation brought about by the pandemic is also driving alcohol consumption. While in the short term alcohol may feel like a stress reliever, research has found that alcohol consumption actually worsens depression and anxiety.”
“Many Canadians exceed Canada’s current low-risk drinking guidelines, which recommend no more than 10 drinks a week for women, and 15 drinks a week for men. These guidelines are now 10 years old and higher than the suggested limits in countries with more up-to-date guidelines including Ireland, France, Australia, UK and the United States,” says Dr Kevin Shield, Independent Scientist, Institute for Mental Health Policy Research, and Head, World Health Organization/Pan American Health Organization Collaborating Centre at the Centre for Addiction and Mental Health. “The health benefits of alcohol are currently overstated and the risks underestimated – most alarmingly, for cancer. Low-risk drinking guidelines also assume people are “free” to choose their consumption, which may not entirely be the case as alcohol is an addictive substance. It would be similar to having low-risk smoking guidelines, which would not make sense as nicotine is addictive.”
To launch the Managing Alcohol Use program, MindBeacon will host a free “Ask a Therapist” webinar on May 19, 2021. Dr. Kevin Shield will be sharing eye-opening new data on alcohol use in Canada and some powerful information about both its physical and mental health affects on Canadians. Dr. Leorra Newman C.Psych, MindBeacon Clinical Content Lead, and Jennifer Baldachin MSW., BSW, MindBeacon therapists will also be answering pressing questions around seeking help for better managing alcohol use and the new therapy program. You can register for the free webinar here.
The Managing Alcohol Use therapy program is available to all Canadian adults seeking mental health support through MindBeacon, whether through MindBeacon’s Workplace Mental Health Program or as a reimbursable benefit through most major Canadian group health benefit plans.
About MindBeacon
MindBeacon provides a continuum of mental healthcare that includes self-guided psychoeducational and wellness content, Peer-to-Peer Support, Direct Messaging Therapy, Therapist Guided Programs and Live Therapy Sessions all offered virtually through their secure and private platform. As one of the first commercially available, digitally-native platforms to offer therapist-assisted internet-based Cognitive Behavioural Therapy in Canada, MindBeacon’s professional service is designed around end users – their health, their way. Working with employers, insurance carriers and government ministries, MindBeacon’s services are accessible, available, affordable and, most importantly, proven to be effective. MindBeacon is changing the therapy landscape by making professional care available to every Canadian, no matter when, where and how they choose to access it.
About The Centre for Addiction and Mental Health (CAMH)
CAMH is Canada's largest mental health and addiction teaching hospital and a world leading research centre in this field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental illness and addiction. CAMH is fully affiliated with the University of Toronto and is a Pan American Health Organization/World Health Organization Collaborating Centre. For more information, please follow @CAMHnews on Twitter.
HAEGARDA® is now available in all of Canada for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients
OTTAWA, ON, May 11, 2021 /CNW/ - CSL Behring Canada announced that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), is now available in all of Canada. HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients.1 HAE patients have absent or low levels of endogenous or functional C1-INH.1 Administration of HAEGARDA replaces the missing or malfunctioning C1-INH protein in patients with HAE.1 The efficacy and safety of HAEGARDA for routine prophylaxis to prevent HAE attacks were demonstrated in a multicenter, randomized, double-blind, placebo-controlled, crossover study which showed that the median percentage reduction in the number of HAE attacks relative to placebo was 95.1% on 60 IU/kg HAEGARDA.1,2
"Hereditary Angioedema (HAE) is a rare disease that results in unpredictable, painful swelling of various body parts which may be potentially life threatening. As a physician that treats this disease, I'm pleased to have HAEGARDA available for patients across Canada. HAEGARDA represents another needed therapeutic advancement for the prevention of HAE as the only Subcutaneous C1 Inhibitor for preventative therapy approved in Canada," said Dr. Stephen D Betschel, Clinical Immunologist and Allergist, St. Michael's Hospital, Toronto.
HAE is caused by deficient or dysfunctional C1-INH, a protein in the blood that helps to control inflammation, and causes the edema attacks associated with the disease. Depending on the severity of the disease, patients could experience several debilitating attacks each month. Laryngeal attacks, which are experienced by more than half of all HAE patients during their lifetime block the airway and can be fatal – with mortality rates as high as 33 percent in untreated patients3,4,5.
HAE Canada commented on the HAEGARDA availability in this statement: "HAE Canada President, Jacquie Badiou, COO, Daphne Dumbrille, and the Board of Directors, are excited that at long last, HAEGARDA is now equally available, without restrictions, to adolescent and adult HAE patients across Canada. This represents yet another milestone for the advancement of care for Canadian HAE patients who need a subcutaneous C1 esterase inhibitor therapy."
CSL Behring Canada also assists patients to get access to training for the administration of HAEGARDA® via the CSL Behring PLUS+ program that offers services and educational materials. Patients can ask their Healthcare professionals to enroll them in the program at any time.
For more information and a complete risk/benefit profile, please contact Customer Service at 1-866-773-7721 ext. 2386 or refer to the Product Monograph available on CSL Behring website at https://www.cslbehring.ca/products/product-list
About Hereditary Angioedema
HAE is a rare genetic disorder caused by a deficient or dysfunctional C1-INH protein. It is inherited in an autosomal dominant manner. Symptoms of HAE include episodes of edema, or swelling, in the hands, the feet, the face, the abdomen, and/or the larynx. Patients who have abdominal attacks of HAE can experience episodes of extreme pain, diarrhea, nausea and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face or throat can result in upper airway closure, asphyxiation and, if untreated, death. Diagnosis of HAE requires a blood test to confirm low or abnormal levels of C1-INH.
About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries. For more information visit www.cslbehring.com and follow us on www.Twitter.com/CSLBehring.
1.
HAEGARDA® Product Monograph. CSL Behring Canada, Inc. August 13, 2019
2.
Longhurst H, Cicardi M, Craig T, et al. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med. 2017;376(12):1131-1140.
3.
Bork K, et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Ach Intern Med. 2003;163:1229-35.
4.
Bork K, et al. Efficacy of different medical therapies for the treatment of acute laryngeal attacks of hereditary angioedema due to C1-esterase inhibitor deficiency. J Emerg Med. 2016;50(4):567-80.
5.
Bork K, et al. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012 Sep;130(3):692-7
SOURCE CSL Behring
Secrets Threaten to Unravel Family Ties in The Wool Over Their Eyes
Dallas, TX, May 10, 2021 — At 18, Natalia Foster knew seven things about the biological father she’d never met: he was tall, dark, handsome and Italian. He was also married to someone other than Natalia’s mother, had three children and, clearly, no morals. Now, at age 28, Natalia knows something new: her father is dying.
The Wool Over Their Eyes, from Dione Martin, is an authentic, heartfelt story about complex family dynamics and the emotions that must be unpacked when long-buried secrets push their way to the surface.
Illegitimate and bi-racial, Natalia is the secret that her father, Joe, planned to take to his grave. His wife and family know nothing of Natalia’s existence — or that her mother is Black — but when word spreads that Joe has only months to live, Natalia feels compelled to meet him and salvage what little time with him she has left. But at what cost to Joe’s devoted wife, Rosa, and their grown children?
In the midst of Natalia’s family drama and pain is also a love story. Natalia must choose between two loves — a long-lost one and a new one. Her ex-boyfriend, Tyler Davis, who captured her heart and connected with her soul, resurfaces. But she meets a handsome doctor, David Duplessis, who’d cared for her father. Just as the relationship begins to blossom, David commits an act that severs her trust and sends her spiraling further into her dark abyss.
The Wool Over Their Eyes is loosely based on Martin’s personal experiences. She drew upon her own memories and insights of growing up without her biological father and being betrayed in her own marriage to inform her narrative and give her characters depth and authenticity.
“I wrote The Wool Over Their Eyes for fatherless girls, for women who have been betrayed, for those who have been rejected because of their race (or otherness) and for families that have been torn apart by secrets, lies and deception,” Martin reflects. “Healing is possible – through change, through empathy, through faith and through forgiveness.”
Author Dione Martin was born and raised in New Orleans, where she spent much of her childhood and teen years reading. She earned her Bachelor’s in English from the University of Minnesota-Morris and her Master’s in Journalism from the University of Texas at Austin. She is currently a senior communications director at Brinker International. She lives in Dallas with her two daughters and enjoys running, cooking, performing arts and attempting DIY projects. The Wool Over Their Eyes is her debut novel, and she is working on her next one.
Chattanooga, TN, May 10, 2021 ― It seems that every day the news gets worse. Mass killings. Officer-involved shootings. Social upheaval. The pandemic. And everyone just trying their best to adjust to a new normal amid swirling unrest. It’s a lot for the brain to process. Do we react with fear? Anxiety? Anger? Or can we teach our brains to push pause and unpack the facts first, instead of allowing the seemingly endless stream of negative news to impact our mental, emotional and spiritual health?
Timothy R. Jennings, M.D., is a board-certified psychiatrist, master psychopharmacologist and highly sought-after speaker who regularly addresses the topic of brain health to both non-medical and medical audiences. His subjects include Major Depression in the Primary Care Setting and the Neurobiology of Depression, Alzheimer’s Dementia, Psychotherapy in Clinical Practice, Spirituality in Medicine, Depression and its Spiritual and Physical Connections — among many others.
A common thread among his discussion topics is how anxiety-inducing news and events can activate the brain’s stress pathways — thereby increasing the body’s inflammatory factors, diminishing immune response and increasing vulnerability to viral infections and cancer. The good news is, we can rewire the way our brains react to negative news and stressful events, and Dr. Jennings can explain how.
As a Christian psychiatrist, Dr. Jennings also speaks to design principles that, when embraced and followed, can lead to a better understanding of the world and bring about more peace.
As the world searches for a clear path toward physical and mental recovery, Dr. Jennings is uniquely poised to address the very serious subject of brain health from both scientific and spiritual perspectives — a much needed and welcomed approach during these extremely distressing times.
Dr. Jennings operates a private practice in Chattanooga and has successfully treated thousands of patients. He is a Distinguished Fellow of the American Psychiatric Association and Life-Fellow of the Southern Psychiatric Association.
###
Blue Hive Health, Canada's First Digital Wellness Clinic Opens Expanding Canadians Access to Personalized Mind-Body Healing
As Canadians suffer from a mental health crisis, Blue Hive Health is on a mission to increase Canadians' access to holistic solutions and improve overall wellbeing.
TORONTO, May 10 2021 /CNW/ - Toronto based Blue Hive Health is Canada's first digital holistic mind-body centre expanding Canadian's access to natural health practices. Using a collaborative educational approach, Blue Hive Health's health and wellness treatments focus on the body, mind and spirit to provide contemporary practices which address multiple aspects of people's wellbeing.
Canadians who report symptoms of mental illness also report experiencing three times as many chronic physical conditions compared to the general population. The correlation between mental and physical health is more pressing now than ever as 1 in every 4 Canadians is dealing with heightened mental health issues due to COVID-19 and its associated lockdowns. With a lack of physical access to health support options Blue Hive Health addresses the gap in the market providing Canadians with an accessible space that serves both mental and physical wellbeing at a time when it is more needed than ever.
With a framework focused on creating a program that is accessible, educational and most importantly, client focused, Blue Hive Health redefines what virtual wellness services can offer and challenges the way health issues are addressed. Rooted in the principle that people's optimal physical health is dependent on positive mental health, Blue Hive's holistic, mind and body approach firmly believes the only way to truly feel true wellbeing is to find and address the root cause of the problem.
"For many health issues, the conventional health care system often focuses on treating the symptoms, rather than targeting and addressing the source of the problem," says Stephanie Abouatallah, Co-founder and CEO, Blue Hive Health. "This approach is needed for some health issues, but falls short for others. We founded Blue Hive Health to increase awareness of the benefits of a holistic, mind and body approach to healing, the range of health issues it can alleviate and how it can enhance conventional treatments."
Blue Hive Health's services include Psychotherapy, Holistic Nutrition, Energetic Therapies, Emotional Freedom techniques, Homeopathy, Naturopathy, Functional Medicine, Mindfulness Meditation and Coaching led by expert practitioners. To provide patients with a full mind-body approach, Blue Hive Health offers one-of-kind Journeys; a curated personalized program designed to help guide a person through the maze of holistic wellness and give them a chance to try different approaches and treatments.
Working with a personal team of practitioners, clients will be introduced to complementary ways to approach their own health journey in a completely custom way. The Journeys include but are not limited to, Stress & Anxiety Relief, Digestive Health Journey, Hormone Rebalancing Journey, Body Positive Journey, Intuitive Eating Journey, Total Body Wellness Journey, as well as custom and corporate programs.
"Blue Hive's Journeys offer a full-mind body approach to healing and introduces a collaborative practice to holistic treatment, designed to support a patient's overall wellbeing," says Giovanna Capozza, Co-Founder and COO, Blue Hive Health. "For many health issues, a remedy often doesn't come from a single treatment. At Blue Hive, patients are able to receive one-on-one time with a team of practitioners, like a Holistic Nutritionist, Personal Coach and Psychotherapist, at significantly reduced rates, who work together on personalized treatment programs."
As COVID-19 continues to sharpen Canadians' focus on their physical health and mental wellbeing, Blue Hive Health is committed to expanding Canadian's understanding of mind-body holistic treatments and demonstrating their positive impact. Through its diverse services which can be tailored to fit in individual needs, Blue Hive Health is on a mission to increase Canadians' access to holistic treatments and support their overall well being,
SOURCE Blue Hive Health
20 Tenets to Help Women Lead Purposeful, Successful Lives Revealed in The Woman Code
Morning Joe Host & Author of Know Your Value, Mika Brzezinski, Pens Foreword
Washington, D.C., May 10, 2021 — The pandemic forced everyone to pivot and re-prioritize, and for many women, that meant putting themselves last. Now, more than ever, women need to know their value, recognize their worth and fill their own cups first.
“Women are the soul of what keeps the world going. We keep our families, our companies, our communities and our nations intact,” explains Sophia A. Nelson, acclaimed journalist and author of The Woman Code: 20 Powerful Keys to Unlock Your Life (April 2021, Health Communications).
Named one of the most inspirational books by Woman’s Day in 2015-2017, this transformative book is updated with new insights about the profound economic and societal shifts that have changed our world since the pandemic. Nelson guides women through living out a powerful life Code that will lead them to purposeful, meaningful and authentically successful lives.
Every woman lives by a Code, whether she realizes it or not. It informs how she treats herself and others and how far she is willing to go in order to find success. Nelson calls on women to examine whether the Code they’re living by is truly helping them create the lives they desire. A senior columnist for USA Today and a frequent commentator on CNN, Nelson reveals 20 powerful Codes including:
Know Your Value
Be Resilient
Choose Your Thoughts and Words Wisely
Lift Other Women as You Climb
Practice Love, Laughter, Loyalty
With life quotes from philosophers and poets, mystics and her maternal grandmother, plus her experience as a Black woman rising through the ranks of a male-dominated news industry, The Woman Code is an essential tool of transformation for women to enjoy in reading groups, retreats and Bible study groups. It will help women honor themselves while navigating the demands of work, home, family and friendship no matter what their age or stage in life.
About the Author
Sophia A. Nelson is an award-winning American author and journalist who appears regularly on CNN’s Inside Politics and Newsroom as a legal and political analyst. She is an adjunct professor in the Department of Philosophy and Religion at Christopher Newport University in Newport News, Virginia.
Nelson covered former First Lady Michelle Obama at the White House from 2010–2012. The author appears frequently on CNN and has been a contributor to MSNBC, NBC, Fox News, the BBC, ABC World News with Diane Sawyer and the Today show. She writes for The Huffington Post Healthy Living and The Daily Beast. She has also contributed to USA Today, Essence, The Wall Street Journal, The New York Times and The Washington Post. She is the author of The Woman Code, Black Woman Redefined, and E Pluribus ONE.
Should a Person with Autism Be Allowed to Become a Professional Boxer and Put His Life at Risk?
Forest, VA, May 10, 2021― It’s a struggle that parents of children with special needs face every day and well into that child’s adulthood: how much decision-making latitude is safe?
NOKI is an empowering story from Douglas Farrago, MD, about a young man with autism who wants to become a professional boxer. Life’s circumstances have dictated the reason for him choosing this path. The lawless world of boxing has its reasons for embracing Noki and his abilities. And they are not good ones. So, the debate wages on: Should Noki be allowed to make the life-altering decision to enter the ring and put his life on the line?
Meanwhile, what few know is that Noki is actually a savant and can imitate and transform himself into any legendary boxer he wants — a plot twist that allows NOKI to pay homage to some of the greatest boxers of all time.
Dr. Farrago draws upon his experiences as an All-American collegiate boxer, a sports medicine trainer for professional boxers in Houston and his decades-long career in medicine during which he worked with autism patients to lend authenticity to his characters and narrative.
“Noki becomes somewhat of a hero to those with special needs in this story, which I think is pretty cool,” he said. “I felt it would be nice if a story showed that those with autism don’t need to be anything but themselves, and maybe it is the rest of us who need to change.”
Ultimately, NOKI is a heartwarming story that will spark real conversations about the limits that society places on people with special needs. Knowingly or not.
Author Douglas Farrago, MD, is board certified in the specialty of Family Practice. Recently retired, he had a large following of autistic and special needs patients in his career. Dr. Farrago is the inventor of the Knee Saver, which is currently in the Baseball Hall of Fame. The Knee Saver and its knock-offs are worn by many major league baseball catchers. He also invented the CryoHelmet, used by athletes for head injuries as well as migraine sufferers.
Dr. Farrago received his Bachelor of Science from the University of Virginia in 1987, his Master of Education degree in Exercise Science from the University of Houston in 1990 and his Medical Degree from the University of Texas at Houston in 1994. His residency training occurred way up north at the Eastern Maine Medical Center in Bangor. Dr. Farrago still blogs every day on his website Authenticmedicine.com and lectures worldwide about the present crisis in our healthcare system and the effect it has on the doctor-patient relationship. Dr. Farrago has written six books to date, his latest one being NOKI.
Ogena Solutions launches ozone-free air purifier proven to kill over 99% of airborne viruses
With safety established by CARB-approval and UL2998 certification, the ozone-free air purifier attacks respiratory droplets and exposed surfaces missed by hand cleaning or HEPA filters
STONEY CREEK, Ontario, May 10, 2021 (GLOBE NEWSWIRE) -- Ogena Solutions, a long-time trusted veteran in leading biosecurity practices, is excited to launch the OgenaShield Air Purifier by Puraclenz. Applying an advanced and patented version of the same technology used to clean air in the International Space Station, the OgenaShield Air Purifier by Puraclenz is one of the most technologically advanced, affordable air purifiers on the market.
“The Covid-19 pandemic has underscored the need for effective air purifying solutions, especially in workplaces and where people congregate. This newly advanced and completely ozone-free system combines UV light with a patented catalyst cell to effectively and efficiently break down and destroy viruses in the air and on exposed surfaces,” says Ogena Solutions President and Founder Dave Hachey.
Third-party tests show that the OgenaShield Air Purifier by Puraclenz kills over 99% of the MS2 Bacteriophage (MS2) virus, an accepted surrogate of SARS-CoV-2, the virus that causes the coronavirus disease COVID-19. The MS2 virus qualified as a surrogate virus since it is a type of virus that is far more difficult to kill than the SARS-CoV-2 virus as well as influenza, norovirus, and the common cold.
The California Air Resource Board (CARB) has approved the OgenaShield Air Purifier by Puraclenz as safe for use in the presence of people and animals. CARB is widely accepted as the world’s gold standard for measuring indoor air quality. The air purifiers also have a UL2998 certification for being completely ozone free.
“We take safety very, very seriously. Since day one of our business, our mission at Ogena Solutions has always been to safeguard animals, people and the environment from pathogens and infectious diseases. We don’t allow any products to enter the market until they’ve been thoroughly tested,” says Hachey.
The air purifier is a partnership with the innovative changemakers at Puraclenz. The newly patented technology behind their air purifiers leverages the power of an advanced form of photocatalytic oxidation (PCO). Unlike most air purifiers, the design does not require viruses to pass through the unit but instead the units increase the number of (already present) positive and negative ions in the air where they deactivate and kill pathogens.
In addition, most air purifiers on the market offer no surface deactivation. The OgenaShield Air Purifier by Puraclenz units kill over 60% of viruses on exposed surfaces – a huge game changer for critical sanitization protocols across all types of businesses.
Ogena Solutions offers three air purifier units with coverage ranging from 500 sq. ft. to 3,000 sq. ft. All are commercial grade and ideal for use in businesses such as gyms, doctor/dental offices, lunchrooms, cafeterias, restaurants, schools, senior housing, manufacturing offices and even agriculture worker housing — basically any type of business establishment.
Our compact and easy-to-install units plug into standard wall outlets and come complete with a wall and ceiling mounting bracket. Some of the key features and benefits of the air purifiers include:
Purifies air and surfaces continuously 24/7.
Eliminates dangerous pathogens.
Single unit coverage of up to 3,000 sq. ft. (30,000 cubic feet) and over multiple rooms, dramatically reducing the number of units needed for full coverage.
Approved as safe for use in the presence of people and animals by the California Air Resource Board. CARB is widely accepted as the world's gold standard for measuring indoor air quality.
UL2998 certification for being completely ozone free.
Long lasting, easy to change UV lamp provides 2.5 years of continuous protection.
Elegant and compact design
Very low operating cost
The units start at $299 USD ($399 CAD), making this product one of the most affordable air purifiers on the market. For more information, visit www.ogenasolutions.com.
AboutOgena Solutions Over the past 16-plus years, Ogena Solutions has forged an identity as one of the most respected animal health biosecurity companies in North America and has been expanding its knowledge and experience into the human health sector. Following a ‘One Health’ philosophy, Ogena Solutions offers innovative, state-of-the-art products and technologies that meet the highest standards for efficacy, efficiency, and safety, providing best-in-class solutions for government agencies, corporations, and small businesses throughout the continent.
Media Cont
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
